about
Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody ResponsesEfficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions.Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platformPreclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2Chitosan-Poly (I:C)-PADRE Based Nanoparticles as Delivery Vehicles for Synthetic Peptide VaccinesHigh-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells.Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.Pre-clinical and clinical development of the first placental malaria vaccine.Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study.Recent advances in the production of recombinant subunit vaccines in Pichia pastoris.Tumour virus vaccines: hepatitis B virus and human papillomavirus.DNA-launched live-attenuated vaccines for biodefense applications.Characterization of the disassembly and reassembly of the HBV glycoprotein surface antigen, a pliable nanoparticle vaccine platform.JC polyomavirus mutants escape antibody-mediated neutralization.Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial.Hepatitis B Vaccines and HPV Vaccines Have Been Hailed as Major Public Health Achievements in Preventing Cancer--Could a Schistosomiasis Vaccine be the Third?Hydroponic Treatment of Nicotiana benthamiana with Kifunensine Modifies the N-glycans of Recombinant Glycoprotein Antigens to Predominantly Man9 High-Mannose Type upon Transient Overexpression.The potential for a protective vaccine for rhinovirus infections.Single-Dose Vaccines.Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia.Characterization of Hemagglutinin Antigens on Influenza Virus and within Vaccines Using Electron Microscopy.HPV prophylactic vaccines: lessons learned from 10 years experience
P2860
Q27493140-0F98C462-76F3-4A88-8F33-26D0A4CA0A5DQ30970916-E5157AFA-3650-4D79-810F-3B53E94DC16EQ34507291-F037EA8F-077B-4AA7-920D-F8E72450C70EQ35591551-0C33A4F9-CA20-4BF5-8A94-50B575B68E7DQ35744303-01D55273-EB8B-4792-A25E-939388B9D8DFQ36101913-F2DCE30C-E60C-40E6-B250-18FCF3FAB3B8Q36957800-D864539F-EB07-480C-90A5-F1BBF3C2E621Q37402846-FFA63E37-070A-4545-8CBC-6071C3BB9EA0Q37710523-FC5F4EEE-3F45-4C3B-B37C-090BF7768B14Q38691920-169E2AD4-78B7-48EF-B878-76016AD281CFQ38733067-CDD9ECB4-7D97-4116-9CE7-85B78E104E0AQ38849581-72B984A3-72C3-4B77-AAC7-3A9809AE78FDQ40046649-D2529C06-415F-4FB6-AADF-3AD1522CF809Q40110791-21409C1A-29EC-458F-917C-C21CB6EEBE66Q40382460-BBC52A6F-8B34-4E17-B9E5-8F35881F6EFDQ40984700-33D4C1DF-4F69-4517-8307-B84C0CAE0E3AQ41929232-A62D0E64-E24A-4A49-8015-C69170738304Q42934235-F18C06D7-E264-485F-8B8F-D7D418F9C468Q49470037-46CB0B43-38C5-458A-9AED-9E868D9FDFC6Q50911439-0D8AB8B7-1C5F-4456-ACE9-A6012E942598Q50979992-A0DF33EA-F436-4F2C-9686-55839F5CA57BQ55262571-2A049FA3-8DE3-4E92-8366-2DAA09E67E5EQ55689231-ECE7E59C-0EDA-44BF-AF1B-350FC59DFFAEQ56067928-2CBEB396-F5DC-4463-BC94-014EE9B6A59A
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Raising expectations for subunit vaccine
@ast
Raising expectations for subunit vaccine
@en
type
label
Raising expectations for subunit vaccine
@ast
Raising expectations for subunit vaccine
@en
prefLabel
Raising expectations for subunit vaccine
@ast
Raising expectations for subunit vaccine
@en
P2860
P356
P1476
Raising expectations for subunit vaccine
@en
P2093
Douglas R Lowy
John T Schiller
P2860
P304
P356
10.1093/INFDIS/JIU648
P407
P577
2014-11-24T00:00:00Z